Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer

Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer

Background: Programmed death ligand 1 (PD-L1) has been used as a diagnostic marker to identify patients that will benefit from immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Immunohistochemistry with E1L3N clone is one of the most widely used and inexpensive laboratory-developed...

Full description

Bibliographic Details
Main Authors: Chen, C. (Author), Chen, G. (Author), Dong, X. (Author), Hou, T. (Author), Li, Y. (Author), Xu, H. (Author), Ye, J. (Author), Zhao, H. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
adult
aged
Aged
Antibodies
antibody
Article
B7-H1 Antigen
Biomarkers, Tumor
cancer tissue
Carcinoma, Non-Small-Cell Lung
CD274 protein, human
clinical evaluation
clone
consistency evaluation
controlled study
E1L3N
female
Female
human
human tissue
Humans
immunohistochemistry
Immunohistochemistry
immunology
immunotherapy
intermethod comparison
laboratory test
Lung Neoplasms
lung tumor
major clinical study
male
Male
metabolism
middle aged
Middle Aged
non small cell lung cancer
non-small cell lung cancer
pathology
PD-L1
procedures
programmed death 1 ligand 1
Prospective Studies
prospective study
protein analysis
protein expression
reliability
tumor marker
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items